The antiproliferative profile of chloroquine (i.e., the classification into three clusters in Figure 4B) showed no significant associations with age, cause of AML (de novo versus secondary), morphological signs of differentiation (FAB classification), expression of the stem cell marker CD34, karyotype, or FLT3-ITD or NPM1 mutations (data not shown). This evidence concerns the gene FLT3 and acute myeloid leukemia.